2019 Archive
Presentation slides and video recordings from the 2019 Heart Failure Update Educational Conference.
← Back to Main ArchiveScientific Sessions & Keynotes
Giannetti
WHAT EVIDENCE DO WE HAVE TO START EVIDENCE-BASED DRUGS IN HOSPITAL?Dr. Nadia GiannettiMedical Director, Heart Failure and Heart Transplant ProgramChief Division of CardiologyMcGill University Health Centre
Virani
POPULATION PRECISION MEDICINE AND SECONDARY PREVENTION OF HEART FAILURESean A. ViraniMD, MSc, MPH, FRCPC, FCCSChief of Cardiology | Providence HealthcarePhysician Program Director | The Heart Centre | St. Paul’s HospitalAssociate Professor of Medicine | UBCPast-President | Canadian Heart Failure Society
McKelvie
ENSURINGTIMELYOPTIMIZATIONIN HEART FAILURE CARE: A SYSTEMSAPPROACHRobert S McKelvie MD PhD FRCPCWestern University and St. Joseph’s Health CareLondon CanadaMay 10, 2019
Nault
SHOULD WE CONSIDER RESCUE CRT?
FridayAM
Fridayam Plenary Qanda
Liu
Liu
Friedrich
Friedrich
Asgar
How to Identify the RIGHT (and WRONG) Patient for Transcatheter Mitral RepairANITAW. ASGARMD, MSC, FRCPC, FACCPROFESSEURAGGREGÉ, UNIVERSITÉDEMONTREALINSTITUTDECARDIOLOGIEDEMONTREAL
Mielniczuk
TO REVASCULARIZE OR NOT TO REVASCULARIZE: IMAGING FOR DECISION-MAKING IN ISCHEMIC CARDIOMYOPATHYLisa M Mielniczuk MD FRCPCAssociate Professor of Medicine, University of Ottawa Heart InstituteUniversity of Ottawa Chair in Heart Function ResearchVice Chair, Patient Quality, Safety and Innovation, Department of Medicine, Ottawa HospitalDirector, Advanced Heart Disease Program
QandA
Qanda
Mak
Mak
Clarke
Brian Clarke MD FRCPC FACCAssociate Professor, University of Calgary, LibinCardiovascular Institute
Lepage
•Consulting Fees/Honoraria: •Novartis, AstraZeneca, Janssen, Servier, Amgen, Sanofi
Ezekowitz
Research burns bright
QandA
Qanda
SATURDAY
Saturday Am Symposium
SATURDAY
Saturday Pm Symposium
Jia
Jia Trainee-Winner
Starling
Starling Introduction
Hanna
WHEN IS LVH NOT JUST LVH?PRACTICAL CLINICAL ALGORITHMS WHEN YOU SUSPECT CARDIAC AMYLOID
Davis
AL AmyloidThe Other GuysMargot Davis, MD MSc FRCPCClinical Assistant ProfessorUniversity of British Columbia
Genge
Angela Genge, MD, FRCP(C)
Fine
Promising Therapies On The Horizon For Treatment Of ATTR AmyloidosisNowell Fine, MD, SM, FRCPCLibinCardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary
QandA
Qanda
SATURDAY
Saturday Joint Symposium
Scientific Slides & Presentations (No Video)
BI LILLY 19 CHFS SS showreel
Welcome and Introductions
CCS Guidelines ENGLISH
Objectives: Co-existing HF and AF•Define the clinical significance and risk profile in this population•Recognize rate, rhythm and device considerations in HF and AF•Discuss the impact of recent clinical trial data relevant to these patients
Carrier V2
INSUFFISANCECARDIAQUEET DIABÈTE
Presenter
INSUFFISANCECARDIAQUEAVANCÉE
Harkness
PRACTICAL APPROACHES TO SELF-CARE MANAGEMENT Harleah Buck RN PhDKaren Harkness RN PhDMay 11, 2019
KimLaflamme
Kim Laflamme Infirmières praticiennes spécialisées aux soins aux adultes Professeure invitée à l’ Université de Montréal.
Liu
Don’t Go Breaking My Heart: Imaging & Prognosis in Takotsubo’s
Mak
INVASIVE MEASUREMENT:THE NEW GOLD STANDARD FOR DIAGNOSIS OF HFpEF?Susanna Mak MD, PhDDirector, Anna Prosserman Heart Function Clinic Harold & Esther Mecklinger and The Posluns Families Cardiac Catheterization Clinical Research LaboratorySinai Health System, University of TorontoMay 11, 2019
McGuinty
•I willdiscussoff-label uses of medications.
NOV
Welcome and
Omeara
Conflitsd’Intérêts•Eileen O’Meara–Honoraires: Amgen, Novartis, Pfizer-BMS, Servier–EssaisCliniques: Amgen, Bayer, Luitpold, National Institutes of Health, Novartis, Merck•Serge Lepage–Consulting Fees/Honoraria: •Novartis, AstraZeneca, Janssen, Servier, Amgen, Sanofi–Clinical Trials: •Novartis, Amgen
Servier
Disruptive Treatment in HF: Combination
Swiggum
HOW AND WHEN TO STOP CARDIAC MEDICATIONS
Presenter
VAD or heart transplantation after age 65
Van Spall and Zieroth